The superfood that helps the heart and is good against fatigue
Jun 11, 2023Menopause: How can women take care of their skin in their 50s and beyond
Jul 28, 2023Studying partial remission of type 1 diabetes in children: New biomarkers and the immunoregulatory role of microRNA
Jun 09, 2023Masculen Titan Male Enhancement Reviews
Jul 02, 2023What are T Cells?
Jun 12, 2023Review of pharmacologic and immunologic agent
Compuscript Ltd
The novel coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak in the last two decades. Emerging and re-emerging infections like COVID-19 pose serious challenges of the paucity of information and lack of specific cure or vaccines. This leaves utilisation of existing scientific data on related viral infections and repurposing relevant aetiologic and supportive therapies as the best control approach while novel strategies are developed and trialled. Many promising antiviral agents including lopinavir, ritonavir, remdesivir, umifenovir, darunavir, and oseltamivir have been repurposed and are currently trialled for the care for COVID-19 patients. Adjunct therapies for the management of symptoms and to provide support especially in severe and critically ill patients have also been identified. This review provides an appraisal of the current evidence for the rational use of frontline therapeutics in the management of COVID-19. It also includes updates regarding COVID-19 immunotherapy and vaccine development.
Keywords: SAR-CoV-2, COVID-19, Respiratory, Drug repurposing, Antiviral, Supportive therapy, Immunotherapy
# # # # # #
Biosafety and Health is sponsored by the Chinese Medical Association, managed by National Institute for Viral
Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC).
For more information, please visit https://www.journals.elsevier.com/biosafety-and-health
Editorial Board: https://www.sciencedirect.com/journal/biosafety-and-health/about/editorial-board
Biosafety and Health is available on ScienceDirect (https://www.sciencedirect.com/journal/biosafety-and-health).
Submissions to Biosafety and Health may be made using Editorial Manager®
(https://www.editorialmanager.com/bsheal/default.aspx).
CiteScore: 4.8
ISSN 2590-0536
# # # # # #
Marzuq A. Ungogo, Mustapha Mohammed, Bala N. Umar, Auwal A. Bala, Garba M. Khalid, Review of pharmacologic and immunologic agents in the management of COVID-19, Biosafety and Health, Volume 3, Issue 3, 2021, Pages 148-155, ISSN 2590-0536, https://doi.org/10.1016/j.bsheal.2021.01.001
Biosafety and Health
10.1016/j.bsheal.2021.01.001
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Highlights Keywords: # # # # # # Editorial Board: Biosafety and Health Biosafety and Health ISSN # # # # # # Disclaimer: